Revenio Group Corporation: Revenio Group Corporation applies for listing of stock options 2015 B

Revenio Group Corporation: Revenio Group Corporation applies for listing of stock options 2015 B

Revenio Group Corporation, Stock Exchange Release, June 15, 2018 at 17.00

Revenio Group Corporation applies for listing of stock options 2015 B

Revenio Group Corporation will apply for the listing of its series B stock options, complying with its 2015 option scheme, on the Nasdaq Helsinki Ltd (Firsth North) as of June 21, 2018.

The total number of the B series stock options under the 2015 option scheme is 50,000. Each option right entitles its holder to subscribe to three (3) Revenio Group Corporation shares. The maximum number of new shares to be issued is 150,000.  Revenio Group Corporation's subsidiary, Done Medical Oy, holds 10,000 series B option rights.

At the moment, the share subscription price under the B series option rights is EUR 10.12 per share. In accordance with the terms and conditions of the option scheme, the subscription price has been reduced by the amount of dividends decided before the share subscription, on the record date of each dividend payment. In accordance with the terms and conditions of the option scheme, the share subscription period for series B option rights begun on May 31, 2018. The option rights are freely transferable as from that date. The subscription period will end on May 31, 2020. The option holders can subscribe the shares during the subscription period by giving the payment and subscription details to their own bank.

The grounds for the granting of the 2015 option rights and the original terms and conditions were published in a stock exchange release on August 10, 2014. The terms and conditions of the option scheme 2015, as well as the approval schedule for share subscriptions under the option rights are available in full on the company's website at www.revenio.fi

Revenio Group Corporation

 

Board of Directors

 

For further information, please contact:

Timo Hildén, CEO, tel.  +358 40 580 4774

timo.hilden@revenio.fi

www.revenio.fi

 

DISTRIBUTION:

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

 

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

 

In 2017, net sales of Revenio Group totaled MEUR 26.8, with an operating margin of 35.5%, excluding non-recurring expenses. Revenio Group Corporation is listed on Nasdaq Helsinki.

 

 

Subscribe